We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Proposes REMS Extension in Alternate Drug Review Strategy
FDA Proposes REMS Extension in Alternate Drug Review Strategy
November 5, 2010
The FDA has proposed allowing a four-month extension to the new drug review cycle under an alternative review strategy if a product has a complicated risk evaluation and mitigation strategy (REMS).